About SCAN-MP

Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations (SCAN-MP)

SCAN-MP is a study conducted at Boston Medical Center, Columbia University Medical Center, and Harlem Hospital funded by the National Institute of Health (NIH). The purpose of this study is to identify undiagnosed cardiac amyloidosis in participants recruited from the African American and Hispanic communities with early non-invasive screening.

Cardiac amyloidosis is caused by myocardial deposition of mis-folded protein. ATTR Cardiac Amyloidosis is defined by the deposition of the transthyretin protein. Cardiac amyloidosis is an under-diagnosed disease that can be an unrecognized cause of heart failure. The overarching goal of the study is to evaluate the prevalence, phenotype, and outcomes of ATTR with genetic and non-genetic causes in the Black and Hispanic populations. The gold standard for diagnosis of cardiac amyloidosis is the heart biopsy. However, this method can delay diagnosis and is an impractical screening method. The study will use Tc99m-pyrophosphate (PYP) imaging for cardiac amyloidosis screening, which has not previously been broadly used to facilitate early diagnosis of cardiac amyloidosis. 

• Who: Self identified Black and Hispanic patients with heart failure
• Where: New York City and Boston
• What: Patients will receive a clinical exam, lab biochemical tests including genetic evaluation, and non-invasive imaging

Click for link to NIH clinical trials site for SCAN-MP

Hear more about SCAN MP from our team:

(In Spanish)

(English)